OOIR: Observatory of International Research

Papers

(The H4-Index of American Journal of Psychiatry is 48. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
Highlights From the Residents’ Journal: December 2021	553
Treating Pathologies of the Will	236
Integrating Clinical and Basic Research: Opioid Use Disorder, Psychotic Illnesses, and Prefrontal Microcircuits Relevant to Schizophrenia	178
Evaluating Associations Between Cannabis and Heroin Use	161
Broadening the Parameters of Clinical High Risk for Psychosis	143
2024 Annual Meeting: Presidential Address	135
From Scanner to Bedside: Building Bridges in Translational Psychiatric Neuroimaging	132
A Call to Psychiatrists: Deprescription of Unnecessary Anticholinergic Medications in Schizophrenia Must Start Now	132
Depression, Inflammation, and Postpartum Psychosis	124
Neural Signatures of Pain Modulation in Short-Term and Long-Term Mindfulness Training: A Randomized Active-Control Trial	112
From Prediction to Action: Moving Beyond Machine Learning to Implementing Evidence-Based Perinatal Mental Health Care	112
Predicting Conversion to Psychosis: What Lies Beyond the Biomarkers?	108
Intentional Drug Overdose Deaths in the United States	104
Can Neuromelanin-Sensitive MRI Provide Insight Into the Dopaminergic Pathways Contributing to Substance Use?	99
Mental Health Disparities Research: An Introduction to New Directions	98
Future of Sensorimotor and Psychomotor Dysfunction in Mental Disorders: Emerging Tools, Methodological Challenges, and the Road Ahead	93
Updates and Advances in the Treatment of Substance Use Disorders, Depression, and Borderline Personality Disorder	92
Effectiveness of Antipsychotic Use for Reducing Risk of Work Disability: Results From a Within-Subject Analysis of a Swedish National Cohort of 21,551 Patients With First-Episode Nonaffective Psychosi	86
Genes To Mental Health (G2MH): A Framework to Map the Combined Effects of Rare and Common Variants on Dimensions of Cognition and Psychopathology	86
20-Year Prospective, Sequential Follow-Up Study of Heterogeneity in Associations of Duration of Untreated Psychosis With Symptoms, Functioning, and Quality of Life Following First-Episode Psychosis	81
Project Harmony: A Meta-Analysis With Individual Patient Data on Behavioral and Pharmacologic Trials for Comorbid Posttraumatic Stress and Alcohol or Other Drug Use Disorders	79
A New Agenda for Optimizing Investments in Community Mental Health and Reducing Disparities	77
Cannabis and Brain Health: What Is Next for Developmental Cohort Studies?	76
Correcting Overestimations in Self-Harm Visit Data	74
Suicide and the Menstrual Cycle	69

Methamphetamine-Induced Psychosis and Schizophrenia: A Call for Special Attention: Response to Zhu et al.	68
An Innovative Approach to Extending the Antidepressant Effects of Intravenous Ketamine in Major Depression	67
Correction to Poirot et al.	66
Corrigendum to Morley et al.	66
2024 Annual Meeting: CEO and Medical Director’s Address	65
New Insights Into Psychotic Disorders	63
Older Adults are at Heightened Risk of the Effects of Cannabis Use: Response to Walaszek	63
Highlights From the Residents’ Journal: September 2024	62
Sensitivity of Schizophrenia Endophenotype Biomarkers to Anticholinergic Medication Burden	60
Back to the Future: Esmethadone, the (Maybe) Nonopiate Opiate, and Depression	60
Trends in Prescription Stimulant, Opioid, and Benzodiazepine Use and Diversion in U.S. Adolescents	59
Primary Prevention of PTSD Symptoms in Combat-Deploying Soldiers Using Attention Bias Modification: A Randomized Controlled Trial	56
The First Large GWAS Meta-Analysis for Postpartum Depression	56
12-month Prevalence Estimates of Substance Use Disorders Using DSM-5 Versus DSM-IV Criteria Among U.S. Nonelderly Adults With Substance Use	54
Schizophrenia Imaging Signatures and Their Associations With Cognition, Psychopathology, and Genetics in the General Population	54
Neural Responses to Intranasal Oxytocin in Youths With Severe Irritability	53
Familial Risk of Postpartum Psychosis	53
Characterizing the Most Vulnerable Prefrontal Cortical Neurons in Schizophrenia	51
Stanford Neuromodulation Therapy (SNT): A Double-Blind Randomized Controlled Trial	51
Similar Rates of Deleterious Copy Number Variants in Early-Onset Psychosis and Autism Spectrum Disorder	51
Durability of Effects of Cognitive Remediation on Cognition and Psychosocial Functioning in Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Clinical Trials	49
Reduced Brain Responsiveness to Emotional Stimuli With Escitalopram But Not Psilocybin Therapy for Depression	48
Risk of Incident Psychosis and Mania With Prescription Amphetamines	48
Scientific Advances Relevant to Schizophrenia, Psychosis, and the Treatment of Methamphetamine Use Disorder	48
Reduced Threat-Related Neural Efficiency: A Possible Biomarker for Pediatric Anxiety Disorders	48